PD-L1 Expression (CPS >= 1) is an inclusion criterion in 18 clinical trials for head and neck squamous cell carcinoma, of which 18 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and head and neck squamous cell carcinoma as inclusion criteria, 6 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), and 9 are phase 2 (9 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 12 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 12 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 12 clinical trials for malignant solid tumor, of which 12 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and malignant solid tumor as inclusion criteria, 9 are phase 1 (9 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 11 clinical trials for gastric adenocarcinoma, of which 11 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and gastric adenocarcinoma as inclusion criteria, 5 are phase 1 (5 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 1 is phase 2/phase 3 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and non-small cell lung carcinoma as inclusion criteria, 6 are phase 1 (6 open) and 2 are phase 2 (2 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 8 clinical trials for oropharyngeal squamous cell carcinoma, of which 8 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 7 clinical trials for hypopharyngeal squamous cell carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 1 is phase 2/phase 3 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 7 clinical trials for laryngeal squamous cell carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 1 is phase 2/phase 3 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 7 clinical trials for oral cavity squamous cell carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (4 open), and 1 is phase 2/phase 3 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 6 clinical trials for urothelial carcinoma, of which 6 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and urothelial carcinoma as inclusion criteria, 4 are phase 1 (4 open) and 2 are phase 2 (2 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 5 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 5 clinical trials for melanoma, of which 5 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and melanoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (2 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and cervical carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 4 clinical trials for renal cell carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and renal cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 2 (2 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 3 clinical trials for esophageal squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 3 clinical trials for gastric carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and gastric carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 3 clinical trials for hepatocellular carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 3 clinical trials for Merkel cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and Merkel cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 3 clinical trials for pancreatic adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and pancreatic adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 3 clinical trials for small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 2 clinical trials for mesothelioma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and mesothelioma as inclusion criteria, 2 are phase 1 (2 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 2 clinical trials for non-squamous non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and ovarian carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 2 clinical trials for skin squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PD-L1 Expression (CPS >= 1) and skin squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for basal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and basal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for carcinoma of unknown primary, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and carcinoma of unknown primary as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for cervical adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and cervical adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for cervical adenosquamous carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and cervical adenosquamous carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and fallopian tube carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and gallbladder carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for peritoneal malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and peritoneal malignant mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for pleural biphasic mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and pleural biphasic mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for pleural epithelioid mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and pleural epithelioid mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for pleural mesothelioma, sarcomatoid type, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and pleural mesothelioma, sarcomatoid type as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and primary peritoneal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for prostate adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and prostate adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PD-L1 Expression (CPS >= 1) is an inclusion criterion in 1 clinical trial for squamous cell carcinoma of unknown primary, of which 1 is open and 0 are closed. Of the trial that contains PD-L1 Expression (CPS >= 1) and squamous cell carcinoma of unknown primary as inclusion criteria, 1 is phase 2 (1 open) [5].